Death receptor DR5 (DR5/TRAIL-R2) is an apoptosisinducing membrane receptor for tumor necrosis factorrelated apoptosis-inducing ligand (TRAIL). In this study, we showed that curcumin, a plant product containing the phenolic phytochemical, is a potent enhancer of TRAILinduced apoptosis through upregulation of DR5 expression. Both treatment with DR5/Fc chimeric protein and silencing of DR5 expression using small interfering RNA (siRNA) attenuated curcumin plus TRAIL-induced apoptosis, showing that the critical role of DR5 in this cell death. Curcumin also induced the expression of a potential proapoptotic gene, C/EBP homologous protein (CHOP), both at its mRNA and protein levels. However, suppression of CHOP expression by small interfering RNA did not abrogate the curcumin-mediated induction of DR5 and the cell death induced by curcumin plus TRAIL, demonstrating that CHOP is not involved in curcumin-induced DR5 upregulation. Taken together, the present study demonstrates that curcumin enhances TRAIL-induced apoptosis by CHOP-independent upregulation of DR5.
Introduction
Tumor necrosis factor (TNF)-a-related apoptosis-inducing ligand (TRAIL), also known as Apo2L, is a cytokine of the TNF family which is capable of inducing apoptotic cell death in a variety of cancer cell types, while having only negligible effects on normal cells (1) (2) (3) . TRAIL binds to four different types of membrane-bound death receptors (DR4, DR5, DcR1 and DcR2). Both DR4 and DR5 contain a conserved cytoplasmic region called the 'death domain' that is required for TRAIL-induced apoptosis (4) (5) (6) . TRAIL also binds to decoy receptors DcR1 and DcR2 that sequester the ligand but are unable to initiate an apoptotic signal (5, 7) . Recent studies have shown that some cancer cells are resistant to the apoptotic effects of TRAIL (8) (9) (10) . TRAIL resistance has been attributed to the loss of TRAIL receptors, upregulation of TRAIL decoy receptors, enhanced expression of cFLIP (cellular Flice-inhibitory protein) or alternations in expression of the Bcl-2 family proteins (11) (12) (13) (14) . However, TRAILresistant cancer cells can be sensitized by the combined treatment with chemotherapeutic drugs and TRAIL in vitro, indicating that combination therapy may overcome TRAIL resistance in cancer cells. Therefore, both the understanding of the molecular mechanisms of TRAIL resistance and the development of the strategies to sensitize these cancer cells to undergo TRAIL-mediated apoptosis are important issues for effective cancer therapy.
Recently, the use of phytochemicals as anti-cancer agent has gained high importance. Curcumin is a major component of the Curcuma species, which possesses anti-proliferative activity against tumor cells in vitro (15) . Moreover, curcumin exhibits anti-carcinogenic activity in vivo, as indicated by its inhibition of tumor promotion induced by various carcinogens or phorbol esters (16) (17) (18) . We have already reported that curcumin induces apoptosis in human renal carcinoma cells and leukemia cells (19, 20) . Renal cell carcinoma remains one of the most drug-resistant malignancies in humans and is a frequent cause of cancer mortality (21) , necessitating the development of novel therapeutic strategies against this type of cancer.
In this study, we investigated the sensitizing effect of curcumin on TRAIL-mediated apoptosis in human renal cancer cells. We found that curcumin treatment results in the upregulation of both DR5 and CHOP, also known as growth arrest and DNA damage-inducible gene 153 (GADD153) (22) . For the first time, we present here the clear evidences that curcumin-induced DR5 upregulation but not CHOP upregulation is critical for its stimulating activity of TRAIL-mediated apoptosis.
oxidase were obtained from Sigma Chemical. Cucumin (Sigma Chemical) was prepared as a 20 mM stock solution in ethanol and final concentration of ethanol in culture medium is <0.2% volume.
Western blotting Cellular lysates were prepared by suspending 1 · 10 6 cells in 100 ml of lysis buffer (137 mM NaCl, 15 mM EGTA, 0.1 mM sodium orthovanadate, 15 mM MgCl 2 , 0.1% Triton X-100, 25 mM MOPS, 100 mM phenylmethylsulfonyl fluoride and 20 mM leupeptin, adjusted to pH 7.2). The cells were disrupted by sonication and extracted at 4 C for 30 min. The whole cell extracts (40 mg) were subjected to 10% SDS-polyacrylamide gel electrophoresis, and electrotransferred to Immobilon-P membranes (Millipore, Bedford, MA). Detection of specific proteins was carried out with an ECL blotting kit according to the manufacturer's instructions.
Cell count and flow cytometry analysis
Cell counts were performed using a hemocytometer. Approximately 1 · 10 6 Caki cells were suspended in 100 ml of PBS, and 200 ml of 95% ethanol were added while vortexing. The cells were incubated at 4 C for 1 h, washed with PBS and resuspended in 250 ml of 1.12% sodium citrate buffer (pH 8.4) together with 12.5 mg of RNase. Incubation was continued at 37 C for 30 min. The cellular DNA was then stained by applying 250 ml of propidium iodide (50 mg/ml) for 30 min at room temperature. The stained cells were analyzed by fluorescent activated cell sorting (FACS) on a FACScan flow cytometer for relative DNA content based on red fluorescence.
Caspase 3 activity assay
To evaluate caspase 3 activity, cell lysates were prepared after their respective treatment with TRAIL or curcumin. Assays were performed in 96-well microtiter plates by incubating 20 mg of cell lysates in 100 ml of reaction buffer (1% NP-40, 20 mM Tris-HCl (pH 7.5), 137 mM NaCl and 10% glycerol) containing the caspases substrate [Asp-Glu-Val-Asp-chromophore p-nitroanilide (DVAD-pNA)] at 5 mM. Lysates were incubated at 37 C for 2 h. Thereafter, the absorbance at 405 nm was measured with a spectrophotometer.
Plasmids, transfections and luciferase gene assays
The human CHOP promoter-containing plasmids have been described previously (23) . The pDR5/SacI plasmid [containing DR5 promoter sequence (À2500/+3)] and pDR5/À605 [containing DR5 promoter sequence (À605/ +3)] were gifts from Dr T Sakai (Kyoto Prefectural University of Medicine, Japan). Point mutations of the CHOP binding sites to the DR5/À605 promoter were generated by a two-step PCR method using the following primers: mCHOP (5-CTTGCGGAGGAGGTAGTTGACGA to 5-TCGTCAACTACC-TCCTCCGAAAG). Clones representing each point mutation were sequenced to ensure the accuracy of the PCR amplification procedure. For transfection, cells were plated onto 6-well plates at a density of 5 · 10 5 cells/well and grown overnight. Cells were co-transfected with 2 mg of various plasmid constructs and 1 mg of the pCMV-b-galactosidase plasmid for 5 h by the Lipofectamine method. After transfection, cells were cultured in 10% FCS medium with vehicle (DMSO) or drugs for 24 h. Luciferase and b-galactosidase activities were assayed according to the manufacturer's protocol (Promega). Luciferase Curcumin sensitizes TRAIL-mediated apoptosis activity was normalized for b-galactosidase activity in cell lysate and expressed as an average of three independent experiments.
RNA isolation and RT-PCR
To determine whether the potential sensitizing effects of curcumin to TRAILmediated apoptosis were a result of increased levels of mRNA encoding CHOP, we compared the levels of CHOP in Caki cells, which were treated with or without various concentrations of curcumin. CHOP mRNA expression was determined by RT-PCR. Total cellular RNA was extracted from cells using the TRIzol reagent (Life Technologies). A cDNA was synthesized from 2 mg of total RNA using M-MLV reverse transcriptase (Gibco-BRL, Gaithersburg, MD). The cDNAs for CHOP and actin were amplified by PCR with specific primers. The sequences of the sense and anti-sense primer for CHOP (accession no. S40706) were 5 0 -CAACTGCAGAGATGGCAGCTGA-3 0 and 5 0 -ACTGATGCTCCCAATTGTTCAT-3 0 , respectively. PCR products were analyzed by agarose gel electrophoresis and visualized by ethidium bromide.
Small interfering RNA (siRNA)
The 25-nt siRNA duplexes used in this study were purchased from Invitrogen (Calsbad, CA) and had the following sequences: DR5, UUU AGC CAC CUU UAU CUC AUU GUC C; and green fluorescent protein (GFP), AAG ACC CGC GCC GAG GUG AAG. Cells were transfected with siRNA oligonucleotides using LipifectAMINE 2000 (Invitrogen, Calsbad, CA) according to the manufacturer's recommendations.
DNA fragmentation assay
After treatment with curcumin, TRAIL, and combination of TRAIL and curcumin for 24 h, Caki cells were lysed in a buffer containing 10 mM Tris (pH 7.4), 150 mM NaCl, 5 mM EDTA and 0.5% Triton X-100 for 30 min on ice. Lysates were vortexed and cleared by centrifugation at 10 000 g for 20 min. Fragmented DNA in the supernatant was extracted with an equal volume of neutral phenol:chloroform:isoamyl alcohol mixture (25:24:1) and analyzed electrophoretically on 2% agarose gels containing 0.1 mg/ml of ethidium bromide.
Results

Curcumin upregulates DR5 and CHOP expressions in various cancer cells
Caki cells, the human renal cancer cells, are resistant to the cytotoxic effect of TRAIL. However, we found that treatment of Caki cells with the subtoxic doses (<30 mM) of curcumin and TRAIL can effectively induce cell death in a dosedependent manner of curcumin ( Figure 1A ). Furthermore, DNA fragmentation analysis by agarose gel electrophoresis showed a typical ladder pattern of internucleosomal DNA fragmentation in Caki cells cotreated with 20 or 30 mM curcumin plus 100 ng/ml TRAIL but not in cells treated with curcumin alone, TRAIL alone and 10 mM curcumin plus 100 ng/ml TRAIL for 24 h ( Figure 1B ). To assess the molecular mechanisms underlying this synergistic induction of apoptosis by curcumin and TRAIL in Caki cells, we examined the effect of curcumin on the expression of apoptosis regulatory proteins by western blotting. Treatment with subtoxic concentrations of curcumin (10-30 mM) did not induce any significant changes in the protein levels of Bcl-2, Bax, XIAP (X-linked inhibitor of apoptosis) and cIAP2 (cellular inhibitor of apoptosis 2) (data not shown). We further analyzed the expressions of various proteins related with DR-mediated apoptotic signaling pathway by western blotting, following treatment of Caki cells with various concentrations of curcumin. Interestingly, DR5, a TRAIL-interacting DR, was significantly and dose-dependently induced in curcumin-treated cells. As shown in Figure 1B , treatment with curcumin slightly induced the expression of DR4 protein in a dose-dependent manner. However, there were no major changes in the protein levels of caspase 8 and Fas associated death domain (FADD) ( Figure 1C) .
Recently, it has been shown that endoplasmic reticulum (ER) stress causes apoptosis (24) and CHOP is a key transcription factor in this process (22) . The ER stress-generated unfolded protein response (UPR) is characterized by increased transcription of ER chaperones, such as Bip/Grp78, which are meant to increase the ER capacity to cope (25) . To investigate whether the sensitizing effect of curcumin on TRAIL-induced apoptosis is associated with ER stress, we assessed the expression levels of CHOP, GADD34, caspase 12 and Grp78 after curcumin treatment. We found that treatment of Caki cells with curcumin induced a dose-dependent increase in the protein levels of CHOP, but did not affect the levels of GADD34, caspase 12 and Grp78 ( Figure 1D ). Treatment with curcumin significantly increased DR5 and CHOP protein levels also in a variety of tumor cell types (colon cancer cells; HCT116 and HT29 and hepatocellular carcinoma HepG2) ( Figure 1E ). These results suggest that upregulation of DR5 and CHOP is a common response of cancer cell lines to curcumin treatment.
Next, we investigated whether the combined treatment with curcumin and TRAIL affects the induction of apoptosis in normal human mesangial cells. The mesangial cells were resistant to 20 mM curcumin or 100 ng/ml TRAIL alone and their morphological change was not significantly affected by the combined treatment with 20 mM curcumin and 100 ng/ml TRAIL. However, the apoptotic characteristics, such as cell shrinkage, apoptotic bodies and detachment from the plate, were frequently observed in Caki cells treated with curcumin plus TRAIL (Figure 2A) . Furthermore, curcumin did not enhance TRAIL-induced apoptosis in normal mesangial cells ( Figure 2B ).
Curcumin activates transcription from the CHOP promoter
To examine whether curcumin-induced CHOP upregulation is controlled at the transcription level, we performed RT-PCR analysis of CHOP in curcumin-treated Caki cells. RT-PCR analysis demonstrated that curcumin enhanced CHOP mRNA levels in a dose-dependent manner ( Figure 3A) . We further attempted to identity the curcumin responsive element in the CHOP promoter. We first examined the effects of curcumin on the promoter activities of reporter constructs containing À954 to +91 region of the CHOP gene promoter region (23) . This construct was transiently transfected into Caki cells, and the response to curcumin was determined by luciferase assay, in the presence or absence of curcumin. As shown in Figure 3B , curcumin increased the promoter activities of À954-CHOPLuc in a dose-dependent manner. Luciferase assay using a series of deletions in this region demonstrates that deletion Curcumin sensitizes TRAIL-mediated apoptosis to À649 had significant effect on the activation of the CHOP promoter by curcumin treatment ( Figure 3C ). In contrast, deletion from À280 decreased the curcumin inducibility and basal activity, suggesting that the region between À649 and À280 contains positive regulatory elements involved in the transcriptional activation of CHOP by curcumin or basal condition.
Pretreatment with N-acetyl-cysteine prevents apoptosis by curcumin plus TRAIL We and other groups have reported that curcumin promotes formation of reactive oxygen species (ROS) (19, 26) . Therefore, we next examined the role of ROS in curcumin plus TRAIL-induced apoptosis using the thiol antioxidant N-acetylcysteine (NAC) (27) . Pretreatment of Caki cells with NAC markedly blocked curcumin plus TRAIL-induced apoptosis ( Figure 4A ). As shown in Figure 4B , cotreatment with curcumin and TRIAL induced downregulation of XIAP proteins. Since XIAP has been previously reported to be a substrate of caspases during apoptosis (28) and pretreatment with z-VAD, a pan-caspase inhibitor, blocked downregulation of XIAP following treatment with curcumin and TRAIL (data not shown), this reduction of XIAP protein levels might be the result of caspase activation in response to the combined treatment, rather than the cause of curcumin-stimulated TRAIL-induced apoptosis. NAC pretreatment significantly inhibited caspase 3 activation, attenuated the cleavage of PLC-g1 and prevented downregulation of XIAP ( Figure 4B ). These data clearly indicate that prevention of curcumin plus TRAIL-induced apoptosis by NAC is associated with the blocking of ROS generation and the subsequent activation of caspases.
Upregulation of CHOP by curcumin appears to be dependent on the formation of reactive oxygen metabolites To investigate whether ROS generation is directly associated with curcumin-induced CHOP upregulation, we assessed the CHOP expression levels in cells treated with an antioxidant NAC or glutathione (GSH) in addition to 30 mM curcumin. As shown in Figure 5A and B, treatment with curcumin significantly increased both the protein and mRNA levels of CHOP, but pretreatment with NAC or GSH markedly inhibited this curcumin-induced CHOP upregulation. Curcumin-mediated increase in CHOP promoter activity, assessed by transient transfection and luciferase assay, was also blocked by pretreatment with NAC ( Figure 5B ). Involvement of ROS in CHOP upregulation was further examined by western blotting of CHOP in cells treated with H 2 O 2 or 10 mM glucose plus glucose oxidase. As shown in Figure 5C , treatment with Figure 5D ). These data clearly indicate that ROS generation is critical for curcumin-induced CHOP upregulation. Previously, we have shown that ROS generation mediates curcumin-induced DR5 upregulation (29) . Therefore, these results suggest the possibility that the blocking effect of NAC on the cell death induced by curcumin plus TRAIL may result from the suppression of curcumin-induced upregulation of CHOP and/or DR5.
CHOP is not involved in the curcumin-induced DR5 upregulation and the cell death induced by curcumin plus TRAIL As Yamaguchi et al. (30) and other groups (31, 32) recently reported that ER stress-mediated CHOP is a potential transcription factor for DR5. To determine whether CHOP plays a role in DR5 upregulation by curcumin, we employed CHOP siRNA. CHOP siRNA markedly reduced the CHOP protein levels but not DR5 protein levels by curcumin treatment ( Figure 6A ). To further clearly determine whether the CHOP is associated with curcumin-mediated transcriptional activation of DR5, we mutated the potential CHOP site (À281 to À261) of the DR5 gene (32) . As shown in Figure 6B , this mutation did not alter the activation of the DR5 promoter by curcumin, demonstrating that CHOP is not involved in the curcumin-mediated upregulation of DR5. Moreover, suppression of CHOP expression by CHOP siRNA did not prevent the sensitization to TRAIL-induced apoptosis by curcumin ( Figure 6C ). These results show that curcumin-induced CHOP upregulation is dispensable for the recovery of TRAIL-sensitivity in Caki cells.
Upregulation of DR5 by curcumin contributes to the enhancement of TRAIL-induced apoptosis in Caki cells
We next examined whether curcumin-induced DR5 upregulation is critical for enhancement of TRAIL-induced apoptosis by curcumin. We first used a recombinant human DR5/Fc chimeric protein, which has a dominant-negative effect by competing with endogenous DR5. As shown in Figure 7A , the curcumin-mediated enhancement of TRAIL-induced apoptosis was significantly blocked by the DR5/Fc chimeric protein. In addition, treatment with DR5/Fc chimeric protein significantly inhibited caspase 3 activation, and attenuated the cleavage of PLC-g1 ( Figure 7B ). These data suggest that interaction of TRAIL with DR5 receptor is important for the sensitizing effect of curcumin on TRAIL-mediated apoptosis. To further determine the protective effect of the Curcumin sensitizes TRAIL-mediated apoptosis DR5/Fc chimeric protein, we performed DNA fragmentation analysis for apoptosis. As shown in Figure 7C , treatment with DR5/Fc chimeric protein effectively inhibited DNA fragmentation induced by curcumin plus TRAIL.
To further confirm the functional significance of curcumin-induced DR5 upregulation, we employed the siRNA duplex against DR5 mRNA. Caki cells transfected with the control GFP or DR5 siRNA were treated with curcumin alone (30 mM), TRAIL alone (100 ng/ml), or combination of curcumin and TRAIL for 24 h and subjected to immunoblot analysis. As shown in Figure 8B , transfection of siRNA against DR5 resulted in a suppression of DR5 expression induced by curcumin in Caki cells, compared with cells transfected with control GFP siRNA. When we evaluated apoptosis by FACS analysis, GFP siRNAtransfected cells showed $54% apoptosis following treatment with curcumin plus TRAIL, however, DR5 siRNA-transfected cells decreased this to 15% ( Figure 8A ). Suppression of DR5 expression in cells transfected with DR5 siRNA significantly inhibited not only caspase 3 activity ( Figure 8B ) but also DNA fragmentation ( Figure 8C ) induced by the combined treatment with curcumin and TRAIL. Taken together, these results suggest that curcumin-induced of DR5 is indispensable for the enhancement of TRAIL-sensitivity in Caki cells.
Discussion
TRAIL is proposed as a based treatment of cancer since it appears to target cancer cells to induce apoptosis while normal cells are resistant to it (5,7). The relative resistance of normal cells to TRAIL has been explained by the presence of large numbers of DcR on normal cells (5, 7) . However, recent studies have been shown that an increasing number of cancers are resistant to TRAIL. One proposed mechanism for this resistance is the presence of intrinsic proteins that can act as inhibitors of apoptosis. FLIP structurally resembles caspase 8 but lacks proteolytic activity, thus functioning as a dominantnegative inhibitor of caspase 8 (33) (34) (35) . Further downstream in the TRAIL-induced apoptotic pathway, Bax mutations (13) or increased expression of IAP family members such as XIAP and survivin, also causes TRAIL resistance (36, 37) . Therefore, new strategies are necessary to overcome TRAIL resistance in cancer cells.
Recently, Deeb et al. (38, 39) reported that a cancer chemopreventive agent curcumin sensitizes prostate cancer cells to TRAIL by inhibiting NF-kB through suppression of IkBa phosphorylation. In this study, we further investigated the ability of curcumin to sensitize TRAIL-induced apoptosis in human renal cancer cells. Recently, we have shown that curcumin induces DR4 and DR5 upregulation (29) , suggesting that curcumin-induced upregulation of these TRAIL receptors may be associated with the significant apoptosis in cells treated with curcumin and TRAIL. Recently studies using affinity assay and phage display of DR-selective TRIAL variants have revealed that DR5 may play a more prominent role than DR4 in TRAIL-mediated apoptotic signals (40, 41) . Following experimental evidences in the present study demonstrate that curcumin-induced DR5 upregulation is essential for curcumin plus TRAIL-induced apoptosis. First, curcumin induces DR5 expression levels more than DR4. Second, both a DR5-specific blocking chimeric antibody and suppression of DR5 expression by siRNA duplexes inhibited the cell death induced by the combination of curcumin and TRAIL in Caki cells. In an attempt to explore the underlying mechanisms involved in curcumin-induced DR5 expression, we tested the possibility that CHOP, a member of the C/EBP family of transcription factors, might be associated with curcumininduced DR5 upregulation. Several papers provide evidence that DR5 upregulation is critical for ER stress (induced by thapsigargin, tunicamycin and brefeldin A)-mediated apoptosis in human cancer cells and CHOP is involved in this process (30, 32, 42) . Additionally, CHOP gene expression is also upregulated when cells were deprived of essential nutrients, and exposed to DNA-damaging agents and anticancer drugs (22, 23) . Our results obtained by luciferase assay using the CHOP-deletion mutants showed that CHOP promoter region from À649 to À280 contain cis-positive elements that are essential for curcumin-induced CHOP regulation. The region from À649 to À280 includes the binding sites for many transcriptional factors such as C/EBP, ATF-2 and SP-1 (23). C/EBPb-deficient cells did not affect the induction of CHOP mRNA by leucine starvation, whereas lack of ATF-2 resulted in a complete loss of the CHOP mRNA induction (23) . In contrast, the induction of CHOP by 15-deoxy-D 12,14 -prostaglandin J 2 has been demonstrated to require C/EBP and ER stress element (43) . Therefore, further studies will be necessary to identify the precise cis-regulatory elements in curcumin-induced CHOP induction.
Recently, Scott et al. (44) have reported that treatment of colon cancer cells with curcumin significantly induced apoptosis accompanying the upregulation of CHOP through the generation of ROS. Similar to their results, subtoxic doses of curcumin induced CHOP upregulation in Caki cells and pretreatment with NAC significantly decreased curcumininduced CHOP upregulation. However, curcumin treatment did not affect the levels of Grp78 (an ER stress response gene product), GADD34 and caspase 12, suggesting that Curcumin sensitizes TRAIL-mediated apoptosis curcumin induces upregulation of CHOP expression though ER stress-independent manner. When we treated Caki cells with curcumin in CHOP transfected cells, neither curcumininduced DR5 upregulation nor the cell death induced by curcumin plus TRAIL was affected. Furthermore, results of the luciferase assay showed that the potential CHOP-binding site is not essential for curcumin-mediated transcriptional activation of the DR5 luciferase plasmid ( Figure 5B ). Previously, we have shown that pretreatment with NAC completely blocks curcumin-induced DR5 upregulation (29) . Taken together, these results suggest that ROS are commonly involved in curcumin-induced DR5 and CHOP upregulation. However, suppression of CHOP expression by its siRNA cannot attenuate the sensitizing effect of curcumin on TRAIL-induced apoptosis, since CHOP is not associated with curcumin-induced DR5 upregulation in Caki cells.
In conclusion, we provide the clear evidences here that curcumin enhances TRAIL-induced apoptosis through the induction of DR5 expression in renal cancer cells. These data raise the possibility that the combination of curcumin and TRAIL may provide an effective therapeutic strategy for the treatment of cancer.
